Financial Post EN

InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China

BEIJING, March 15, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 […]

Mar 16, 2026 &03401616202631; 01:40 UTC financialpost.com Trending 3/5

Read original on financialpost.com ↗

↗

Positive for markets

Sentiment score: +65/100

Moderate impact Medium-term (weeks)

WHAT THIS MEANS

InnoCare Pharma announced the first healthy volunteer dosing in a clinical trial of ICP-538, a novel VAV1 degrader in China. This represents an important milestone in the development of a potentially differentiated therapeutic for cancer and autoimmune diseases, advancing the company's pipeline.

AI CONFIDENCE

75% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

09969.HK

09969.HKStock

Expected to rise

Clinical trial milestone achievement for novel VAV1 degrader demonstrates pipeline progress and validates therapeutic approach

↑

688428.SS

688428.SSStock

Expected to rise

First-in-human dosing of ICP-538 represents de-risking event for biotech company with cancer and autoimmune disease focus

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Monitor InnoCare's stock for potential upside on clinical trial progression updates. Consider accumulating on any weakness as early-stage biotech milestones typically drive positive sentiment; watch for safety and efficacy data releases over the next 12-24 months.

KEY SIGNALS

First healthy volunteer dosed - clinical trial advancementNovel VAV1-directed molecular glue degrader mechanismDual indication potential (cancer and autoimmune diseases)China-based trial executionDe-risking of pipeline asset

SECTORS INVOLVED

BiotechnologyPharmaceuticalsHealthcare

Analysis generated on Mar 16, 2026 at 11:13 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China

RELATED INTELLIGENCE